← Leaderboards
Zarife Sahenk
Research Inst Nationwide Children'S Hosp
$5,260,424
Attributed
$5,260,424
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2007–18$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$5,260,424 · 5
By mechanism
U54$2,034,115 · 2
U01$1,537,318 · 1
R01$1,375,170 · 1
R21$313,821 · 1
Top collaborators
No co-investigators on record.
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Kevin M Flanigan$19,837,604
- Louise R. Rodino-Klapac$1,192,155
- Christopher M. Walker$28,677,697
- Amanda Haidet-Phillips$85,308
Others in their field
Top investigators on “Outcome Measure”
- Paul S. Aisen · Cognition Therapeutics, Inc.$161,347,534
- Reisa A. Sperling · Banner Health$133,857,863
- Randall J Bateman · Washington University$124,655,201
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$108,065,597
- Eric Martin McDade · Washington University$96,219,353
- James E. Gern · University Of Wisconsin-Madison$90,069,547
Research focus
Outcome MeasureSuccessGene TherapyGene ExpressionMuscleImmunosuppressive AgentsImmuneTissuesMorphologyMacaca MulattaQuality ControlRoutine Histology Staining MethodMissionLaboratoriesHistopathologyResearch PersonnelBaseComputer SoftwareMolecularBlood VesselsMicro-DystrophinHistologicImmunohistochemistryReporting
Grant awards (15)
Neurotrophin-3 gene therapy for Charcot-Marie-Tooth 1A$1,375,170
R01 · FY2018 · NS · contact PI
Lentivirus Transduced Tolerogenic Dendritic Cells For The Treatment Of CIDP$155,318
R21 · FY2015 · NS · contact PI
Histopathology core$160,566
U54 · FY2014 · HD · contact PI
Lentivirus Transduced Tolerogenic Dendritic Cells For The Treatment Of CIDP$158,503
R21 · FY2014 · NS · contact PI
Histopathology core$141,239
U54 · FY2013 · HD · contact PI
NT-3 gene therapy to improve peripheral nerve function induced by genetic defect$838,587
U01 · FY2012 · NS · contact PI
Histopathology core$165,296
U54 · FY2012 · HD · contact PI
NT-3 gene therapy to improve peripheral nerve function induced by genetic defect$353,308
U01 · FY2011 · NS · contact PI
Histopathology core$159,923
U54 · FY2011 · HD · contact PI
NT-3 gene therapy to improve peripheral nerve function induced by genetic defect$345,423
U01 · FY2010 · NS · contact PI
Histopathology Core$259,222
U54 · FY2010 · NS · contact PI
Histopathology core$136,800
U54 · FY2010 · HD · contact PI
Histopathology Core$352,114
U54 · FY2009 · NS · contact PI
Histopathology Core$341,928
U54 · FY2008 · NS · contact PI
Histopathology Core$317,027
U54 · FY2007 · NS · contact PI